Journal of Biochemistry and Biotechnology

Editorial - Journal of Biochemistry and Biotechnology (2018) Volume 1, Issue 1

Inhibition of LIM kinase inhibits cancer growth

Juliana Antonipillai1* and Sam L Francis2

1Western Centre for Health and Research Education, Victoria University, Australia

2St Vincent’s Hospital, The University of Melbourne, Australia

*Corresponding Author:
Juliana Antonipillai
Western Centre for Health Research and Education (WCHRE)
Sunshine Hospital, 176 Furlong Road, St Albans, VIC, 3021, Australia
E-mail: [email protected]

Accepted date: 12 August, 2017

Citation: Juliana A, Sam LF. Inhibition of LIM kinase inhibits cancer growth. J Biochem Biotech. 2017;1(1):4-5.

Visit for more related articles at Journal of Biochemistry and Biotechnology


The LIM kinase family of serine protein kinases contains two members, LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2). LIMK1 was first isolated from olfactory epithelial cell lines [1], and LIMK2 from a rat cDNA library using human LIMK1 cDNA as a probe [2]. LIMK1 and 2 are structurally similar and share 50% amino acid homology, human and mouse LIMK1 share 95% amino acid homology. The amino terminus of LIMK contains two double zinc finger LIM domains, followed by a PDZ domain. Both domains are involved in protein-protein interaction [3].

The C-terminus end of the molecule contains the catalytic active kinase domain. LIMK proteins are about 70kDa in size and are expressed in the cytoplasm of most adult and embryonic mouse tissues as well as human tissues [4]. Furthermore, the LIMK1 protein is significantly expressed in highly invasive breast and prostate cancer lineages compared to less invasive cell lines [5].

Dynamics of LIMK and Actin

ADF/cofilin, is a well-known substrate of the LIMK molecule, it acts as an actin depolymerization factor. LIMK interacts with to phosphorylate cofilin resulting in inactivation. Cofilin promotes actin depolymerization in the cell by hydrolysing actin filaments (F-actin) and sequestering the monomers (G-actin) from the polymerizing end (Figure 1).


Figure 1: A model for LIMK signalling cascade in normal cells. LIMK activity is controlled by several molecules. While the Rho associated kinase (ROCK) and p21 activated kinases (PAKs) activate LIMK, Bone morphogenetic protein receptor II (BMPRII), dominant-negative form of LIMK (LIMKs) and Slingshot phosphatise (SSH-IL) inhibit its activity. Active LIMK promotes filamentous actin (F-actin) in cells by phosphorylating its substrate cofilin. But dephosphorylated LIMK is inactive and so promotes G-actin.

Phosphorylated cofilin looses its binding affinity toward the actin molecule leading to inhibition of the hydrolysis process, thus increasing polymerized filamental actin in the cells. Downstream Rho GTPases such as PAK1, PAK 4 and ROCK phosphorylate and activate LIMK molecules leading to activation of F-actin, whereas BMPRII, SSH-1L and the dominant form of LIMK, known as LIMKs, inactivate the molecule to promote G-actin. Coordinating together with other signaling molecules, the downstream LIMK signaling cascade is also involved in the homeostasis of actin dynamics under physiological conditions.

LIMK and microtubule dynamics

Microtubule (MT) destabilization promotes the formation of actin stress fibers and enhances the contractility of cells. Gorovoy et al. identified that LIMK1 is associated with MTs via their PDZ domain, and is involved in MT destabilization [6]. Moreover, phosphorylated LIM kinases (pLIMK1/2) are co-localized with gamma-tubulin in the centrosomes during the early mitotic phases of human breast and prostate cancer cells. In addition co-localization begins in the centrosomes during prophase and terminates during early telophase. However, accumulation of pLIMK1/2 at the cleavage furrow was noted. This observation suggests that activated LIMK1/2 may be associated with gamma-tubulin and play a role in mitotic spindle assembly [7].

LIMK expression and cancer metastasis

LIMK regulates the actin tredmilling process. Changes in actin polymerization are important features of motile cells. One of the hallmarks of metastatic cells is their ability to spread from the original site to other parts of the body ‘metastasize’.

Cell motility is the result of coordination between membrane protrusive activity at a leading edge, movement of the cell body and retraction of the cell rear. Actin polymerization at the leading edge can physically drive membrane protrusion. Cofilin phosphorylation is essential for cell movement and since LIMK1 is the major cofilin kinase, it must be involved in cell movement [8,9].

LIMK expression levels were elevated in metastatic cancer cells. We have demonstrated that the level of endogenous LIMK1 protein is markedly elevated in a large number of locally invasive breast and prostate cancer cell lines [10] as well as metastatic human tumours from breast, colon, skin and prostate. Bagheri-Yarmand et al. observed increased LIMK1 levels in metastatic breast cancer tissues.

Their studies demonstrated that cells over expressing LIMK1 have increased levels of the serine protease urokinase type plasminogen activator (uPA) and its receptor (uPAR), furthermore they suggested that LIMK1 enhances tumour invasion by up-regulating the uPA system and inducing uPA secretion [10]. uPA is important for degradation of the extracellular matrix and facilitating cell motility.

LIMK and therapeutic target

LIMKs are an excellent target point for cancer therapy as they function to regulate the major intracellular network systems of microtubule dynamics and the actin cytoskeleton. Cell growth, invasion and migration were significantly reduced when kinase activity or gene expression of LIMKs were inhibited. Inhibition can be achieved via LIMK specific inhibitor molecules or via gene knockdown techniques, this has been shown in breast and lung cancer cells [11,12]. Recent research outcomes demonstrated that inhibition of LIMK activity blocks tumor progression not only via regulating actin dynamics but also by disrupting mitotic microtubule organization [13-16].